Discover undervalued stocks with Eulerpool.

Subscribe for $2

Manhattan Scientifics Stock MHTX

Price

0
Today +/-
-0
Today %
-0 %

Manhattan Scientifics stock price

Loading chart...
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Manhattan Scientifics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Manhattan Scientifics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Manhattan Scientifics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Manhattan Scientifics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Manhattan Scientifics Stock Price History

DateManhattan Scientifics Price
9/19/20250 undefined
9/19/20250.00 undefined
9/8/20250.00 undefined

Manhattan Scientifics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Manhattan Scientifics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Manhattan Scientifics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Manhattan Scientifics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Manhattan Scientifics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Manhattan Scientifics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Manhattan Scientifics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Manhattan Scientifics’s growth potential.

Manhattan Scientifics Revenue, EBIT and net profit per share

DateManhattan Scientifics RevenueManhattan Scientifics EBITManhattan Scientifics Net Income
20230 undefined-703,000 undefined-1.17 M undefined
202250,000 undefined-680,000 undefined-2.73 M undefined
202150,000 undefined-690,000 undefined-3.64 M undefined
202050,000 undefined-680,000 undefined4.31 M undefined
2019100,000 undefined-1.03 M undefined-1.22 M undefined
20180 undefined-1.44 M undefined-8.33 M undefined
2017140,000 undefined-2.28 M undefined1.55 M undefined
2016150,000 undefined-6.38 M undefined-6.11 M undefined
201560,000 undefined-6.25 M undefined8.01 M undefined
2014640,000 undefined-3.48 M undefined-3.81 M undefined
2013650,000 undefined-1.81 M undefined-1.93 M undefined
2012690,000 undefined-1.65 M undefined-2.09 M undefined
2011690,000 undefined-2.17 M undefined-2.29 M undefined
20101.69 M undefined10,000 undefined-40,000 undefined
2009630,000 undefined-400,000 undefined-450,000 undefined
20080 undefined-2.15 M undefined-2.14 M undefined
20070 undefined-3.44 M undefined-3.01 M undefined
20060 undefined-1.94 M undefined-1.69 M undefined
20050 undefined-1.62 M undefined-220,000 undefined
2004150,000 undefined-2.13 M undefined-1.52 M undefined

Manhattan Scientifics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (k)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (k)
NET INCOME (M)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
20012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0000000001,0000000000000000
-----------------------
---------100.00-------------
0000000001,0000000000000000
-6-4-2-10-1-3-200-2-2-1-38-61-8-14-3-2-1
--33.33-50.00-50.00--200.00-33.33-----50.00200.00-366.67-175.00-116.67-900.00-87.50-500.00-175.00-33.33-50.00
110.92122.01156.15174.41181.01194.58249.57328.47393.16401.92425.58449.7461.11485.63593.45534.68533.78533.78549.36593.05559.28559.28559.28
- - - - - - - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Manhattan Scientifics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Manhattan Scientifics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (k)
OTHER REC. (M)
INVENTORIES (M)
OTHER CURRENT LIAB. (k)
CURRENT ASSETS (M)
TANGIBLE ASSETS (k)
LONG-T. INVEST. (M)
LONG-T. REC. (k)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (M)
TOTAL ASSETS (M)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (M)
RETAINED EARNINGS (M)
OTHER EQUITY (k)
UNREAL. GAINS/LOSSES (M)
EQUITY (M)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (k)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (k)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (M)
2002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                           
0.070.060.120.360.150.450.70.511.120.190.110.582.535.361.070.270.090.260.350.230.180.07
000000000170260000400000000
0000000000000000000000
0000000000000000000000
3080220150104008090240160100001010101020102
0.10.140.340.510.160.490.70.591.210.60.530.592.535.361.110.280.10.270.360.250.190.07
6040504030000050301501402901701010010000
0.1000000000000005.511.351.055.882.90.840.25
00000000000000000600300000
1.381.030.820.610.40.190.290.290.261.451.281.120.960.790.630.02000000
0000000000000000000000
0.020.030.1000.030.0300.4600006.425.735.031.200000
1.561.10.970.650.430.220.320.290.721.51.311.271.17.56.5310.572.561.656.192.90.840.25
1.661.241.311.160.590.711.020.881.932.11.841.863.6312.867.6410.852.661.926.553.151.030.32
                                           
0.120.170.180.180.20.320.380.40.410.440.461.531.581.61.591.591.591.621.621.621.621.62
40.8842.7343.643.9544.949.1151.2951.6952.7354.9856.2356.7361.8963.6263.5367.2967.2967.6369696969
-41.49-44.06-45.57-45.79-47.49-50.5-52.64-53.09-53.13-55.42-57.51-59.44-63.24-55.23-61.34-59.66-67.97-69.2-64.88-68.52-71.25-72.42
-1400000013015070302000000000000
0000000000000000000000
-0.63-1.16-1.79-1.66-2.39-1.07-0.84-0.850.080.03-0.8-1.180.239.993.789.220.910.055.742.1-0.63-1.8
1.340.431.231.221.520.360.280.220.270.250.230.390.430.831.340.210.220.230.160.10.120.13
0000.260.320.40.550.490.330.370.370.020.020.010.111.421.531.860.851.131.441.92
00000000000000000000010
0.941.951.871.361.131.031.031.030.480.681.351.351.350.450.2800000.130.110.06
0000000000000000000000
2.282.383.12.842.971.791.861.741.081.31.951.761.81.291.731.631.752.091.011.361.672.12
000000000.550.550.451.291.621.932.14000.080.1000
0000000000000000000000
0000000023023025000000000000
000000000.780.780.71.291.621.932.14000.080.1000
2.282.383.12.842.971.791.861.741.862.082.653.053.423.223.871.631.752.171.111.361.672.12
1.651.221.311.180.580.721.020.891.942.111.851.873.6513.217.6510.852.662.226.853.461.040.32
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Manhattan Scientifics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Manhattan Scientifics's financial health and stability.

Assets

Manhattan Scientifics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Manhattan Scientifics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Manhattan Scientifics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Manhattan Scientifics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (k)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (k)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (k)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (k)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES ()
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022
-6-4-2-10-1-3-200-2-2-1-38-61-8-14-3-2
0000000000000001,000000000
0000000000000000000000
0000000000000000000000
3110-1011000001-50-360-432
0000000000000000000000
0000000000000000000000
-2000000000-1-10-23-4000000
0000000000000000000000
00001,00000000000000000000
00001,00000000000000000000
0000000000000000000000
0000001,000000001,0001,00000000000
0000000000000300000000
0000000000011400000000
----------------------
0000000000000000000000
-100000000000012-4000000
-2.37-0.93-0.25-0.46-0.75-0.33-0.54-0.7-0.410.46-1.2-1.08-1.14-2.583.16-4.57-0.8-0.68-0.32-0.39-0.42-0.35
0000000000000000000000

Manhattan Scientifics stock margins

The Manhattan Scientifics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Manhattan Scientifics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Manhattan Scientifics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Manhattan Scientifics's sales revenue. A higher gross margin percentage indicates that the Manhattan Scientifics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Manhattan Scientifics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Manhattan Scientifics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Manhattan Scientifics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Manhattan Scientifics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Manhattan Scientifics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Manhattan Scientifics Margin History

Manhattan Scientifics Gross marginManhattan Scientifics Profit marginManhattan Scientifics EBIT marginManhattan Scientifics Profit margin
2023100 %0 %0 %
2022100 %-1,360 %-5,460 %
2021100 %-1,380 %-7,280 %
2020100 %-1,360 %8,620 %
2019100 %-1,030 %-1,220 %
2018100 %0 %0 %
2017-35.71 %-1,628.57 %1,107.14 %
2016100 %-4,253.33 %-4,073.33 %
2015100 %-10,416.67 %13,350 %
2014100 %-543.75 %-595.31 %
2013100 %-278.46 %-296.92 %
2012100 %-239.13 %-302.9 %
201184.06 %-314.49 %-331.88 %
201092.31 %0.59 %-2.37 %
2009100 %-63.49 %-71.43 %
2008100 %0 %0 %
2007100 %0 %0 %
2006100 %0 %0 %
2005100 %0 %0 %
2004100 %-1,420 %-1,013.33 %

Manhattan Scientifics Stock Sales Revenue, EBIT, Earnings per Share

The Manhattan Scientifics earnings per share therefore indicates how much revenue Manhattan Scientifics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Manhattan Scientifics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Manhattan Scientifics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Manhattan Scientifics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Manhattan Scientifics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Manhattan Scientifics Revenue, EBIT and net profit per share

DateManhattan Scientifics Sales per ShareManhattan Scientifics EBIT per shareManhattan Scientifics Earnings per Share
20230 undefined-0 undefined-0 undefined
20220 undefined-0 undefined-0 undefined
20210 undefined-0 undefined-0.01 undefined
20200 undefined-0 undefined0.01 undefined
20190 undefined-0 undefined-0 undefined
20180 undefined-0 undefined-0.02 undefined
20170 undefined-0 undefined0 undefined
20160 undefined-0.01 undefined-0.01 undefined
20150 undefined-0.01 undefined0.01 undefined
20140 undefined-0.01 undefined-0.01 undefined
20130 undefined-0 undefined-0 undefined
20120 undefined-0 undefined-0 undefined
20110 undefined-0.01 undefined-0.01 undefined
20100 undefined0 undefined-0 undefined
20090 undefined-0 undefined-0 undefined
20080 undefined-0.01 undefined-0.01 undefined
20070 undefined-0.01 undefined-0.01 undefined
20060 undefined-0.01 undefined-0.01 undefined
20050 undefined-0.01 undefined-0 undefined
20040 undefined-0.01 undefined-0.01 undefined

Manhattan Scientifics business model

Manhattan Scientifics Inc is an innovative company that operates in the world of science and technology. The company was founded in 1994 by Marvin Maslow and is based in New York City. It primarily focuses on developing advanced technologies in the fields of materials science, biotechnology, and medical technology. The business model of Manhattan Scientifics Inc is based on the discovery and development of new technologies, which are then licensed or sold. The company specializes in technology development and works closely with scientific institutions and researchers around the world. In the past, the company has collaborated closely with NASA and the Los Alamos National Laboratory, and has been able to bring several successful products to market. The various divisions of Manhattan Scientifics Inc include nanotechnology, biotechnology, and medical technology. In the field of nanotechnology, the company has developed advanced technologies for the production of ultralight, highly strong materials. These materials are used in aerospace, construction, and other industries where lightweight and durable materials are needed. The biotechnology division of Manhattan Scientifics Inc focuses on the development of novel therapies for cancer and other diseases. The company has successfully developed a new cancer therapy based on magnetic nanoparticles. These nanoparticles are introduced into the body and attach to cancer cells. They are then attracted and killed by an external magnetic field. Medical technology is another important division of Manhattan Scientifics Inc. The company has developed advanced technologies for the production of medical devices that provide more precise surgeries and treatments. One of Manhattan Scientifics Inc's successful innovations is a device that can precisely target tumors with high-energy radiation to destroy them. Manhattan Scientifics Inc has brought several successful products to market in the past. One example of such a product is the Greenshift Corporation System, which helps reduce emissions from airplanes. The company has also had successful collaborations with NASA on various projects, including the development of super-lightweight carbon fiber components. Overall, Manhattan Scientifics Inc is an innovative company that specializes in the development of new technologies. The company has successfully worked in various fields, including nanotechnology, biotechnology, and medical technology. Its business model is based on the discovery and development of new technologies, which are then licensed or sold. Through its collaborations with scientific institutions and researchers around the world, the company has developed and brought several successful products to market. Manhattan Scientifics is one of the most popular companies on Eulerpool.com.

Manhattan Scientifics SWOT Analysis

Strengths

  • Advanced technological solutions and patents that provide a competitive advantage.
  • Diversified portfolio of innovative products in various industries.
  • Strong R&D capabilities and a team of experts driving innovation.

Weaknesses

  • Limited market presence and brand recognition compared to larger competitors.
  • Relatively small financial resources and potential constraints on scaling up operations.
  • Dependence on key customers or partners for revenue generation.

Opportunities

  • Growing demand for cutting-edge technologies in the healthcare, energy, and environmental sectors.
  • Expansion into new markets and partnerships with established industry players.
  • Potential for strategic acquisitions to enhance product offerings and market reach.

Threats

  • Intense competition from larger, well-established companies with greater resources.
  • Rapidly changing technological landscape requiring constant adaptation.
  • Regulatory hurdles and legal challenges for certain products or markets.
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Manhattan Scientifics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Manhattan Scientifics historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Manhattan Scientifics shares outstanding

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Manhattan Scientifics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Manhattan Scientifics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Manhattan Scientifics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Manhattan Scientifics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Manhattan Scientifics.

Manhattan Scientifics shareholders

%
Name
Stocks
Change
Date
6.08429 % Maslow (Marvin)34,028,27303/29/2024
5.26338 % Georgiou (Photios Frank)29,437,07503/29/2024
4.10004 % Tsoupanarias (Emmanuel)22,930,77303/29/2024
0 % SVB Wealth LLC0-645,0003/31/2025
1

Manhattan Scientifics Executives and Management Board

Mr. Marvin Maslow

(85)
Manhattan Scientifics Chairman of the Board (since 1998)
Compensation 861,667

Mr. Emmanuel Tsoupanarias

(70)
Manhattan Scientifics President, Chief Executive Officer, Director (since 2015)
Compensation 186,000
1

Most common questions regarding Manhattan Scientifics

What values and corporate philosophy does Manhattan Scientifics represent?

Manhattan Scientifics Inc represents values of innovation, technological advancement, and financial growth. With a strong corporate philosophy centered on groundbreaking research and development, the company strives to provide cutting-edge solutions in the field of nanotechnology. Through its commitment to excellence and staying at the forefront of scientific progress, Manhattan Scientifics Inc aims to deliver innovative products and services that can impact various industries. This forward-thinking approach has earned the company a reputation for driving change and bringing transformative technologies to market. By focusing on these core values, Manhattan Scientifics Inc continues to pave the way for advancements in nanotechnology and contribute to the future of scientific exploration.

In which countries and regions is Manhattan Scientifics primarily present?

Manhattan Scientifics Inc is primarily present in the United States of America.

What significant milestones has the company Manhattan Scientifics achieved?

Manhattan Scientifics Inc has achieved significant milestones throughout its history. One notable accomplishment is the development of the NanoMRX platform, a cutting-edge technology for detecting cancer. Additionally, the company has successfully commercialized its revolutionary Magnetic Field Applicator (MFA) for the treatment of cancerous tumors. Manhattan Scientifics Inc has also made substantial progress in the field of nanotechnology, with breakthrough advancements in high-performance metals and alloys. These achievements demonstrate the company's commitment to innovation and its continual pursuit of advancements in the fields of medicine and materials science.

What is the history and background of the company Manhattan Scientifics?

Manhattan Scientifics Inc. is a technology-focused company established in 1992. With headquarters in New Mexico, the company has centered its efforts around the development and commercialization of innovative technologies. Leveraging its expertise in nano-materials and nano-composites, Manhattan Scientifics has pioneered advancements in areas such as cancer detection and treatment, imaging diagnostics, and homeland security. Through strategic partnerships and collaborations, the company has successfully introduced groundbreaking products and solutions to the market. As an industry leader, Manhattan Scientifics continues to drive innovation and deliver cutting-edge technologies that address critical global challenges, positioning itself for future growth and success.

Who are the main competitors of Manhattan Scientifics in the market?

The main competitors of Manhattan Scientifics Inc in the market include companies such as General Electric Company (GE), Siemens AG, and Philips Electronics N.V. These industry leaders also operate in the healthcare and nanotechnology sectors, competing with Manhattan Scientifics Inc in areas such as medical imaging, diagnostics, and innovative material applications.

In which industries is Manhattan Scientifics primarily active?

Manhattan Scientifics Inc is primarily active in the industries of advanced materials and nanotechnology.

What is the business model of Manhattan Scientifics?

The business model of Manhattan Scientifics Inc is centered around the commercialization of disruptive technologies in the areas of medicine and nanotechnology. The company aims to bring innovative solutions to market that can significantly improve patient outcomes and advance the field of healthcare. With a focus on developing and licensing proprietary technologies, Manhattan Scientifics Inc works closely with strategic partners to accelerate the adoption and commercial success of their products. By leveraging their expertise and intellectual property portfolio, the company strives to create value for its shareholders and contribute to the advancement of scientific research and development.

What is the P/E ratio of Manhattan Scientifics 2025?

The P/E ratio cannot be calculated for Manhattan Scientifics at the moment.

What is the P/S ratio of Manhattan Scientifics 2025?

The P/S cannot be calculated for Manhattan Scientifics currently.

What is the Quality Investing of Manhattan Scientifics?

The Quality Investing for Manhattan Scientifics is 5/10.

What is the revenue of Manhattan Scientifics 2025?

The revenue cannot currently be calculated for Manhattan Scientifics.

How high is the profit of Manhattan Scientifics 2025?

The profit cannot currently be calculated for Manhattan Scientifics.

What is the business model of Manhattan Scientifics

Manhattan Scientifics Inc is an American company that was founded in 1994. The company is based in New York and is involved in the development of innovative technologies in various fields. Its main focus is on nanotechnology, where it develops materials and systems that operate at the nano scale using nanoparticles and nanofibers. It also operates in the biotechnology sector, focusing on researching cancer and other serious diseases. Additionally, it develops technologies in the field of renewable energy, such as new battery technologies. Manhattan Scientifics aims to establish its technologies in the market through collaborations and spin-off companies. Its most well-known products include lightweight and durable materials used in aircraft and automotive industries, as well as a platform for precise manufacturing of medical devices. Overall, Manhattan Scientifics specializes in the development and marketing of technologies and products in various fields, aiming to increase their dissemination and market success through partnerships and new ventures.

What is the Manhattan Scientifics dividend?

Manhattan Scientifics pays a dividend of 0 USD distributed over payouts per year.

How often does Manhattan Scientifics pay dividends?

The dividend cannot currently be calculated for Manhattan Scientifics or the company does not pay out a dividend.

What is the Manhattan Scientifics ISIN?

The ISIN of Manhattan Scientifics is US5631221000.

What is the Manhattan Scientifics WKN?

The WKN of Manhattan Scientifics is 911936.

What is the Manhattan Scientifics ticker?

The ticker of Manhattan Scientifics is MHTX.

How much dividend does Manhattan Scientifics pay?

Over the past 12 months, Manhattan Scientifics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Manhattan Scientifics is expected to pay a dividend of 0 USD.

What is the dividend yield of Manhattan Scientifics?

The current dividend yield of Manhattan Scientifics is .

When does Manhattan Scientifics pay dividends?

Manhattan Scientifics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Manhattan Scientifics?

Manhattan Scientifics paid dividends every year for the past 0 years.

What is the dividend of Manhattan Scientifics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Manhattan Scientifics located?

Manhattan Scientifics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Manhattan Scientifics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Manhattan Scientifics from 10/5/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/5/2025.

When did Manhattan Scientifics pay the last dividend?

The last dividend was paid out on 10/5/2025.

What was the dividend of Manhattan Scientifics in the year 2024?

In the year 2024, Manhattan Scientifics distributed 0 USD as dividends.

In which currency does Manhattan Scientifics pay out the dividend?

The dividends of Manhattan Scientifics are distributed in USD.

All fundamentals about Manhattan Scientifics

Our stock analysis for Manhattan Scientifics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Manhattan Scientifics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.